published by Celine May 08, 2022 at 3:27 p.m
For several years, the pharmaceutical industry has been vying for its ingenuity to successfully develop the most effective and least invasive treatments for obesity. And it turns out that pharmaceutical giant Eli Lilly and Company has succeeded to develop a promising new experimental treatment!
The latter would indeed lose about 24 kg! This would be the same as this completely spectacular result observed during bariatric surgery.
A new anti-obesity drug lets you lose up to 50 pounds!
This is what the researchers at Eli Lilly and Company wanted to base their research on the control of two incretin hormones, GIP and GLP-1. Both are involved in mediating satiety in their natural state. It should also be known that on this subject there is already a drug on the market that controls GLP-1. And it turns out that the latter has already proven its worth in patients with obesity. But the new experimental treatment Let’s be revolutionary!
GIP and GLP-1 are hormones that are naturally synthesized in the gut itself. These trigger the feeling of fullness at the end of a meal. Previous studies had already shown that GIP reduces appetite and increases energy expenditure at the same time. Which, as you can imagine, promotes weight loss. This hormone is linked to the activation of GLP-1 receptors can have a much greater impact. And to regulate the markers of metabolic derailment, such as glucose and lipids in particular.
Extremely satisfactory clinical studies!
Phase 3 clinical trials involved 2539 people from nine countries divided into 5 groups. These people were all obese and weighed an average of 105 kg. They were then asked to receive weekly injections of 5 mg tirzepatide for 72 weeks and according to their group. 10mg. 15mg. Or even a placebo plus a reference treatment.
The group that received the highest dose of tirzepatide recorded an average weight loss of 24 kilograms! what a stands for 22.5% decrease in body weight. Versus 2.4% for the group receiving a placebo. Unbelievable, is not it?